Accordingly, the NCCN Guidelines for invasive breast cancer (version 1.2022) recommend assessment for PIK3CA mutations using tumor tissue or ctDNA testing, with reflex tumor testing if the ctDNA results are negative [2]. Here, PIK3CA is linked to invasive breast carcinoma.